A LUHMES 3D dopaminergic neuronal model for neurotoxicity testing allowing long-term exposure and cellular resilience analysis

Archives of Toxicology

Volumn 90, Issue 11, 2016, Pages 2725-2743

  Smirnova, L ^a   Harris, G ^a   Delp, J ^b   Valadares, M ^a   Pamies, D ^a   Hogberg, H T ^a   Waldmann, T ^b   Leist, M ^b   Hartung, T ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

3D culture; microRNA; Neurotoxicity; Resilience; Rotenone

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; ALPHA SYNUCLEIN; ARGININOSUCCINATE SYNTHASE; BETA TUBULIN; CHEMOKINE RECEPTOR CXCR6; CYSTATHIONINE GAMMA LYASE; DOPAMINE TRANSPORTER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLYCINE HYDROXYMETHYLTRANSFERASE; KI 67 ANTIGEN; MICRORNA; MICRORNA 16; MICRORNA 210; MICRORNA 7; NESTIN; RED FLUORESCENT PROTEIN; ROTENONE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER MEMBER 2; ANTIPARKINSON AGENT; NERVE PROTEIN; NEUROPROTECTIVE AGENT; NEUROTOXIN; PHOTOPROTEIN; RECOMBINANT PROTEIN;

ARTICLE; CARBON METABOLISM; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMORTALIZED CELL LINE; LONG TERM EXPOSURE; LUHMES CELL CULTURE; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL TOXICITY; MOLECULAR PATHOLOGY; NERVE CELL CULTURE; NERVE CELL DIFFERENTIATION; NEURITE; NEUROPATHOLOGY; NEUROTOXICITY; PARKINSON DISEASE; PRIORITY JOURNAL; SULFATION; AGONISTS; ANTAGONISTS AND INHIBITORS; CELL AGGREGATION; CELL CULTURE TECHNIQUE; CELL DIFFERENTIATION; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; DRUG RESISTANCE; EVALUATION STUDY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PRECLINICAL STUDY; PROCEDURES; THREE DIMENSIONAL IMAGING; TOXICITY TESTING; TRANSFORMED CELL LINE;

ANTIPARKINSON AGENTS; CELL AGGREGATION; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL LINE, TRANSFORMED; CELL SURVIVAL; DOPAMINERGIC NEURONS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE; GENE EXPRESSION REGULATION; HUMANS; IMAGING, THREE-DIMENSIONAL; LUMINESCENT PROTEINS; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; NERVE TISSUE PROTEINS; NEURITES; NEUROPROTECTIVE AGENTS; NEUROTOXINS; RECOMBINANT PROTEINS; TOXICITY TESTS, ACUTE; TOXICITY TESTS, CHRONIC;

EID: 84949509769     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-015-1637-z     Document Type: Article

References (86)

1. Alépée N, Bahinski A, Daneshian M et al (2014) State-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology. ALTEX 31:441–477. doi:10.14573/altex1406111
2. Ascherio A, Chen H, Weisskopf MG, O’Reilly E, McCullough ML, Calle EE, Schwarzschild MA, Thun MJ (2006) Pesticide exposure and risk for Parkinson’s disease. Ann Neurol 60:197–203. doi:10.1002/ana.20904
3. Bandiera S, Matégot R, Girard M et al (2013) MitomiRs delineating the intracellular localization of microRNAs at mitochondria. Free Radic Biol Med 64:12–19. doi:10.1016/j.freeradbiomed.2013.06.013
4. Betarbet R, Sherer TB, MacKenzie G et al (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 3:1301–1306. doi:10.1038/81834
5. Borland MK, Trimmer PA, Rubinstein JD et al (2008) Chronic, low-dose rotenone reproduces Lewy neurites found in early stages of Parkinson’s disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells. Mol Neurodegener. doi:10.1186/1750-1326-3-21
6. Buck KB, Zheng JQ (2002) Growth cone turning induced by direct local modification of microtubule dynamics. J Neurosci 22:9358–9367. doi:10.1016/0959-4388(94)90030-2
7. Chan YC, Banerjee J, Choi SY, Sen CK (2012) miR-210: the master hypoxamir. Microcirculation 19:215–223. doi:10.1111/j.1549-8719.2011.00154.x
8. Chinta SJ, Andersen JK (2005) Dopaminergic neurons. Int J Biochem Cell Biol 37:942–946. doi:10.1016/j.biocel.2004.09.009
9. Choi DC, Chae Y-J, Kabaria S et al (2014) MicroRNA-7 protects against 1-methyl-4-phenylpyridinium-induced cell death by targeting RelA. J Neurosci 34:12725–12737. doi:10.1523/JNEUROSCI.0985-14.2014
10. Constantinescu R, Constantinescu AT, Reichmann H, Janetzky DB (2007) Neuronal differentiation and long-term culture of the human neuroblastoma line SH-SY5Y. Neuropsychiatric disorders an integrative approach. Springer, Vienna, pp 17–28
11. Costello S, Cockburn M, Bronstein J et al (2009) Parkinson’s disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol 169:919–926. doi:10.1093/aje/kwp006
12. Derda R, Laromaine A, Mammoto A et al (2009) Paper-supported 3D cell culture for tissue-based bioassays. Proc Natl Acad Sci USA 106:18457–18462. doi:10.1073/pnas.0910666106
13. Dityatev A, Fellin T (2008) Extracellular matrix in plasticity and epileptogenesis. Neuron Glia Biol 4:235–247. doi:10.1017/S1740925X09000118
14. Efrémova L, Schildknecht S, Adam M et al (2015) Prevention of the degeneration of human dopaminergic neurons in an astrocyte co-culture system allowing endogenous drug metabolism. Br J Pharmacol. doi:10.1111/bph.13193
15. Fragkouli A, Doxakis E (2014) miR-7 and miR-153 protect neurons against MPP(+)-induced cell death via upregulation of mTOR pathway. Front Cell Neurosci 8:182. doi:10.3389/fncel.2014.00182
16. Franco-Iborra S, Vila M, Perier C (2015) The Parkinson disease mitochondrial hypothesis: where are we at? Neuroscientist. doi:10.1177/1073858415574600
17. Frischknecht R, Gundelfinger ED (2012) The brain’s extracellular matrix and its role in synaptic plasticity. Adv Exp Med Biol 970:153–171. doi:10.1007/978-3-7091-0932-8_7
18. Fujita KA, Ostaszewski M, Matsuoka Y et al (2014) Integrating pathways of Parkinson’s disease in a molecular interaction map. Mol Neurobiol 49:88–102. doi:10.1007/s12035-013-8489-4
19. Gerhardt E, Kügler S, Leist M et al (2001) Cascade of caspase activation in potassium-deprived cerebellar granule neurons: targets for treatment with peptide and protein inhibitors of apoptosis. Mol Cell Neurosci 17:717–731. doi:10.1006/mcne.2001.0962
20. Giraldez AJ, Cinalli RM, Glasner ME et al (2005) MicroRNAs regulate brain morphogenesis in zebrafish. Science 308:833–838. doi:10.1126/science.1109020
21. Grau CM, Greene LA (2012) Use of PC12 cells and rat superior cervical ganglion sympathetic neurons as models for neuroprotective assays relevant to Parkinson’s disease. Methods Mol Biol 846:201–211. doi:10.1007/978-1-61779-536-7_18
22. Greene LA, Tischler AS (1976) Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA 73:2424–2428. doi:10.2307/65785
23. Gu J, Firestein BL, Zheng JQ (2008) Microtubules in dendritic spine development. J Neurosci 28:12120–12124. doi:10.1523/JNEUROSCI.2509-08.2008
24. Hama H, Kurokawa H, Kawano H et al (2011) Scale: a chemical approach for fluorescence imaging and reconstruction of transparent mouse brain. Nat Neurosci 14:1481–1488. doi:10.1038/nn.2928
25. Hartung T and Leist M (2008) Food for thought.. on the evolution of toxicology and the phasing out of animal testing. ALTEX 25(2):91-102
26. Hartung T (2014) 3D: a new dimension of in vitro research. Adv Drug Deliv Rev. doi:10.1016/j.addr.2014.04.003
27. Henchcliffe C, Beal MF (2008) Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 4:600–609. doi:10.1038/ncpneuro0924
28. Hengstler JG, Marchan R, Leist M (2012) Highlight report: towards the replacement of in vivo repeated dose systemic toxicity testing. Arch Toxicol 86:13–15. doi:10.1007/s00204-011-0798-7
29. Hogberg, HT, Bressler, J, Christian, KM, Harris, G, Makri, G, O'Driscoll, C, et al. (2013) Toward a 3D model of human brain development for studying gene/environment interactions. Stem Cell Research & Therapy 4 Suppl 1, S4–S4. doi:10.1186/scrt365
30. Honegger P, Monnet-Tschudi F (2001) Aggregating neural cell cultures. Protocols for neural cell culture. Humana Press, New York, pp 199–218
31. Hu W, He Y, Xiong Y et al (2015) Derivation, expansion, and motor neuron differentiation of human-induced pluripotent stem cells with non-integrating episomal vectors and a defined xenogeneic-free culture system. Mol Neurobiol. doi:10.1007/s12035-014-9084-z
32. Huang W, Li MD (2009) Nicotine modulates expression of miR-140*, which targets the 3′-untranslated region of dynamin 1 gene (Dnm1). Int J Neuropsychopharmacol 12:537–546. doi:10.1017/S1461145708009528
33. Huang TT, Liu YY, Huang MM et al (2010) Wnt1-cre-mediated conditional loss of Dicer results in malformation of the midbrain and cerebellum and failure of neural crest and dopaminergic differentiation in mice. Fen Zi Xi Bao Sheng Wu Xue Bao 2:152–163. doi:10.1093/jmcb/mjq008
34. Junn E, Lee K-W, Jeong BS, Chan TW, Im JY, Mouradian MM (2009) Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci USA 106:13052–13057. doi:10.1073/pnas.0906277106
35. Kaidery NA, Tarannum S, Thomas B (2013) Epigenetic landscape of Parkinson’s disease: emerging role in disease mechanisms and therapeutic modalities. Neurotherapeutics 10:698–708. doi:10.1007/s13311-013-0211-8
36. Kim JH, Auerbach JM, Rodriguez-Gomez JA et al (2002) Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson’s disease. Nature 418:50–56
37. Kim J, Inoue K, Ishii J et al (2007) A MicroRNA feedback circuit in midbrain dopamine neurons. Science 317:1220–1224. doi:10.1126/science.1140481
38. Kim JH, Park SG, Song S-Y et al (2013) Reactive oxygen species-responsive miR-210 regulates proliferation and migration of adipose-derived stem cells via PTPN2. Cell Death Dis 4:e588. doi:10.1038/cddis.2013.117
39. Krause K-H, van Thriel C, De Sousa PA et al (2013) Monocrotophos in Gandaman village: India school lunch deaths and need for improved toxicity testing. Arch Toxicol 87:1877–1881. doi:10.1007/s00204-013-1113-6
40. Krug AK, Balmer NV, Matt F et al (2013) Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants. Arch Toxicol 87:2215–2231. doi:10.1007/s00204-013-1072-y
41. Krug AK, Gutbier S, Zhao L et al (2014) Transcriptional and metabolic adaptation of human neurons to the mitochondrial toxicant MPP(+). Cell Death Dis 5:e1222. doi:10.1038/cddis.2014.166
42. Kumar Singh N, Dev Banerjee B, Bala K et al (2014) Gene–gene and gene-environment interaction on the risk of Parkinson disease. Curr Aging Sci 7(2):101–109
43. Lancaster MA, Renner M, Martin C-A et al (2013) Cerebral organoids model human brain development and microcephaly. Nature 501:373–379. doi:10.1038/nature12517
44. Langston JW, Langston EB, Irwin I (1984) MPTP-induced parkinsonism in human and non-human primates–clinical and experimental aspects. Acta Neurol Scand Suppl 100:49–54
45. Lau P, de Strooper B (2010) Dysregulated microRNAs in neurodegenerative disorders. Semin Cell Dev Biol. doi:10.1016/j.semcdb.2010.01.009
46. Lee J-W, Cannon JR (2015) LRRK2 mutations and neurotoxicant susceptibility. Exp Biol Med (Maywood). doi:10.1177/1535370215579162
47. Leist M, Hartung T (2013) Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice. Arch Toxicol 87(4):563-7 doi:10.1007/s00204-013-1038-0
48. Leist M, Hasiwa N, Rovida C, Daneshian M, Basketter D, Kimber I, Clewell H, Gocht T, Goldberg A, Busquet F, Rossi AM, Schwarz M, Stephens M, Taalman R, Knudsen TB, McKim J, Harris G, Pamies D, Hartung T (2014) Consensus report on the future of animal-free systemic toxicity testing. ALTEX 31(3):341-56. doi:10.14573/altex.1406091
49. Leucht C, Stigloher C, Wizenmann A et al (2008) MicroRNA-9 directs late organizer activity of the midbrain-hindbrain boundary. Nat Neurosci 11:641–648. doi:10.1038/nn.2115
50. Li X, Jin P (2010) Roles of small regulatory RNAs in determining neuronal identity. Nat Publ Group 11:329–338. doi:10.1038/nrn2739
51. Li P, Jiao J, Gao G, Prabhakar BS (2012) Control of mitochondrial activity by miRNAs. J Cell Biochem 113:1104–1110. doi:10.1002/jcb.24004
52. Lingor P, Unsicker K, Krieglstein K (1999) Midbrain dopaminergic neurons are protected from radical induced damage by GDF-5 application. J Neural Transm 106:139–144
53. Lotharius J, Falsig J, van Beek J et al (2005) Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. J Neurosci 25:6329–6342. doi:10.1523/JNEUROSCI.1746-05.2005
54. Maertens A, Luechtefeld T, Kleensang A, Hartung T (2015) MPTP’s pathway of toxicity indicates central role of transcription factor SP1. Arch Toxicol 89:743–755. doi:10.1007/s00204-015-1509-6
55. Miller RL, Miller RL, James-Kracke M et al (2009) Oxidative and inflammatory pathways in Parkinson’s disease. Neurochem Res 34:55–65. doi:10.1007/s11064-008-9656-2
56. Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6:583–592. doi:10.1038/nrc1893
57. Miranda RC, Pietrzykowski AZ, Tang Y et al (2010) MicroRNAs: master regulators of ethanol abuse and toxicity? Alcohol Clin Exp Res 34:575–587. doi:10.1111/j.1530-0277.2009.01126.x
58. Mouradian MM (2012) MicroRNAs in Parkinson’s disease. Neurobiol Dis 46:279–284. doi:10.1016/j.nbd.2011.12.046
59. NRC—National Research Council, Committee on Toxicity Testing and Assessment of Environmental Agents (2007) Toxicity testing in the 21st century: a vision and a strategy. The National Academies Press, Washington, DC
60. Pallocca G, Fabbri M, Sacco MG et al (2013) miRNA expression profiling in a human stem cell-based model as a tool for developmental neurotoxicity testing. Cell Biol Toxicol 29:239–257. doi:10.1007/s10565-013-9250-5
61. Rahnenführer J, Leist M (2015) From smoking guns to footprints: mining for critical events of toxicity pathways in transcriptome data. Arch Toxicol 89:813–817. doi:10.1007/s00204-015-1497-6
62. Saba R, Störchel PH, Aksoy-Aksel A et al (2012) Dopamine-regulated microRNA MiR-181a controls GluA2 surface expression in hippocampal neurons. Mol Cell Biol 32:619–632. doi:10.1128/MCB.05896-11
63. Schildknecht S, Pöltl D, Nagel DM et al (2009) Requirement of a dopaminergic neuronal phenotype for toxicity of low concentrations of 1-methyl-4-phenylpyridinium to human cells. Toxicol Appl Pharmacol 241:23–35. doi:10.1016/j.taap.2009.07.027
64. Schildknecht S, Karreman C, Pöltl D et al (2013) Generation of genetically-modified human differentiated cells for toxicological tests and the study of neurodegenerative diseases. ALTEX 30:427–444
65. Schlachetzki JCM, Saliba SW, de Oliveira ACP et al (2012) Studying neurodegenerative diseases in culture models. Rev Bras Psiquiatr 35:S92–S100. doi:10.1590/1516-4446-2013-1159
66. Schmittgen TDT, Livak KJK (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3:1101–1108. doi:10.1038/nprot.2008.73
67. Scholz D, Pöltl D, Genewsky A et al (2011) Rapid, complete and large-scale generation of post-mitotic neurons from the human LUHMES cell line. J Neurochem 119:957–971. doi:10.1111/j.1471-4159.2011.07255.x
68. Selenica M-L, Jensen HS, Larsen AK et al (2007) Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Br J Pharmacol 152:959–979. doi:10.1038/sj.bjp.0707471
69. Smirnova L, Sittka A, Luch A (2012) On the role of low-dose effects and epigenetics in toxicology. EXS 101:499–550. doi:10.1007/978-3-7643-8340-4_18
70. Smirnova L, Block K, Sittka A et al (2014) MicroRNA profiling as tool for in vitro developmental neurotoxicity testing: the case of sodium valproate. PLoS ONE 9:e98892. doi:10.1371/journal.pone.0098892
71. Smirnova L, Seiler AEM, Luch A (2015a) microRNA profiling as tool for developmental neurotoxicity testing (DNT). Curr Protoc Toxicol. doi:10.1002/0471140856.tx2009s64
72. Smirnova L, Harris G, Leist M, Hartung T (2015b) Cellular resilience. ALTEX 32(4):247
73. Srikanth P, Young-Pearse TL (2014) Stem cells on the brain: modeling neurodevelopmental and neurodegenerative diseases using human induced pluripotent stem cells. J Neurogenet 28:5–29. doi:10.3109/01677063.2014.881358
74. Stępkowski TM, Wasyk I, Grzelak A, Kruszewski M (2015) 6-OHDA-induced changes in Parkinson’s disease-related gene expression are not affected by the overexpression of PGAM5 in in vitro differentiated embryonic mesencephalic cells. Cell Mol Neurobiol. doi:10.1007/s10571-015-0207-5
75. Stiegler NV, Krug AK, Matt F, Leist M (2011) Assessment of chemical-induced impairment of human neurite outgrowth by multiparametric live cell imaging in high-density cultures. Toxicol Sci 121:73–87. doi:10.1093/toxsci/kfr034
76. Tal TL, Tanguay RL (2012) Non-coding RNAs: novel targets in neurotoxicity. Neurotoxicology 33:530–544. doi:10.1016/j.neuro.2012.02.013
77. Tanner CM, Kamel F, Ross GW et al (2011) Rotenone, paraquat, and Parkinson’s disease. Environ Health Perspect 119:866–872. doi:10.1289/ehp.1002839
78. Todorovic M, Newman JRB, Shan J, Bentley S, Wood SA, Silburn PA, Mellick GD (2014) Comprehensive assessment of genetic sequence variants in the antioxidant ‘master regulator’ nrf2 in idiopathic Parkinson’s disease. PLoS ONE 10:e0128030. doi:10.1371/journal.pone.0128030
79. van Vliet EE, Morath SS, Eskes CC et al (2008) A novel in vitro metabolomics approach for neurotoxicity testing, proof of principle for methyl mercury chloride and caffeine. Neurotoxicology 29:1–12. doi:10.1016/j.neuro.2007.09.007
80. van Vliet E, Daneshian M, Beilmann M et al (2014) Current approaches and future role of high content imaging in safety sciences and drug discovery. ALTEX 31:479–493. doi:10.14573/altex.1405271
81. Volbracht C, van Beek J, Zhu C et al (2006) Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity. Eur J Neurosci 23:2611–2622. doi:10.1111/j.1460-9568.2006.04787.x
82. Wang A, Costello S, Cockburn M et al (2011) Parkinson’s disease risk from ambient exposure to pesticides. Eur J Epidemiol 26:547–555. doi:10.1007/s10654-011-9574-5
83. Wheeler HE, Wing C, Delaney SM et al (2015) Modeling chemotherapeutic neurotoxicity with human induced pluripotent stem cell-derived neuronal cells. PLoS ONE 10:e0118020. doi:10.1371/journal.pone.0118020
84. Yamaguchi Y (2000) Lecticans: organizers of the brain extracellular matrix. Cell Mol Life Sci 57:276–289
85. Yang D, Li T, Wang Y et al (2012) miR-132 regulates the differentiation of dopamine neurons by directly targeting Nurr1 expression. J Cell Sci 125:1673–1682. doi:10.1242/jcs.086421
86. Zhang X-M, Yin M, Zhang M-H (2014) Cell-based assays for Parkinson’s disease using differentiated human LUHMES cells. Acta Pharmacol Sin 35:945–956. doi:10.1038/aps.2014.36